Compare Costco Wholesale Corporation (COST) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Danaher Corporation — how do they compare? Costco Wholesale Corporation trades at $941.98 (market cap $422.52B), while Danaher Corporation trades at $207 (market cap $147.18B). The key difference: Costco Wholesale Corporation is far larger — about 2.9× Danaher Corporation's market cap, and Danaher Corporation pays the higher dividend (0.76%). Which is the better fit depends on your goals.
| COST | DHR | |
|---|---|---|
Market Cap | $422.52B | $147.18B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $242.05 |
52-Week Low | $849.63 | $161.91 |
Enterprise Value | $410.66B | $169.39B |
Dividend Yield | 0.62% | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $952.75, up 0.52% with a neutral technical outlook. The stock shows strong fundamentals with revenue growth from $254.5B in 2024 to $275.2B in 2025 and net income reaching $8.1B. Recent March sales surged 11.3% year-over-year to $28.41B. Valuation metrics remain elevated with P/E at 47.93 and P/S at 1.44. Analyst consensus is strongly bullish with 65.5% buy ratings and a $1,120 price target.
The investment case centers on Costco's membership-driven profit engine and consistent execution, though high valuation presents near-term risk. Upside potential exists if the company maintains its premium growth trajectory, while any earnings disappointment could trigger valuation compression. The recent membership fee increase and strong renewal rates support margin expansion prospects.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
